Nav: Home

Stem cell therapy furthers research for infants with hypoplastic left heart syndrome

July 22, 2019

ROCHESTER, Minn. -- A phase I clinical trial is the first research monitored by the Food and Drug Administration that demonstrates the potential of regenerative therapy for hypoplastic left heart syndrome (HLHS) through collecting, processing and injecting an infant's own stem cells directly into the heart at the time of surgery. A paper detailing the clinical trial was published in The Journal of Thoracic and Cardiovascular Surgery.

The study focused on the safety and feasibility of stem cell treatments designed to strengthen the heart muscle of children with hypoplastic left heart syndrome, a severe congenital heart disease. The research is funded by the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome at Mayo Clinic and Mayo Clinic.

Hypoplastic left heart syndrome affects approximately 1,000 infants in the U.S. each year. In these babies, the left side of the heart is critically underdeveloped, requiring surgical intervention to support remaining function in the right side of the heart. Patients with hypoplastic left heart syndrome undergo three staged reconstructive surgeries. The Norwood surgery is typically performed within the first days of life. The Glenn surgery takes place within the first few months of age. And the Fontan operation is performed at 2 to 4 years of age.

Since HLHS is rare, no single hospital can treat enough of these patients to advance research with the scope, scale and pace provided by Mayo Clinic's HLHS Consortium, says Tim Nelson, M.D., Ph.D., senior author and director of the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome. Within this growing collaboration, seven hospitals and an advocacy group work together to provide care for HLHS patients across the U.S. The combined efforts of treatment teams facilitate the sharing of care options and information that benefit patients, families and research.

The phase I clinical trial studied 10 babies diagnosed with hypoplastic left heart syndrome before birth, each enrolled in the ongoing Mayo Clinic Umbilical Cord Blood Collection Study. A minimum of 35 milliliters of cord blood was collected at the time of birth using a specialized collection kit. Then this blood was sent to Mayo Clinic for processing and storage. Mayo Clinic's Human Cellular Therapy Laboratories and ReGen Theranostics Inc. manufactured a highly concentrated specialized stem cell product that could be stored and then shipped back to the hospital to be directly thawed and injected into the heart muscle at the time of the baby's second surgery.

"The infrastructure is now in place to collect and process stem cells with this method for any HLHS baby born in the U.S.," Dr. Nelson says.

Each patient underwent the first surgery and then received his or her processed stem cells during the second operation. This study was a first for using a cell-based therapy by direct injection during heart surgery in children. The study team was required to gather three months of follow-up data from the first child before administering the injection to the second child, and likewise for the third.

All 10 patients successfully underwent the second surgery with injection of stem cells directly into the heart. There were no deaths, and none of the children had any significant safety concerns over six months following surgery.

"We now have a reproducible protocol to utilize stem cell therapy in babies with HLHS. Our hopes are that this groundbreaking research will lead to stem cell therapy strengthening these babies' hearts while delaying or even preventing the need for a heart transplant in some," says Harold Burkhart, M.D., a pediatric cardiothoracic surgeon at OU Medicine in Oklahoma and first author on the paper.

The HLHS Consortium is now conducting a larger phase IIb study with 50 infants. This study focuses on testing the ability of the stem cells to improve heart function. This study also is enrolling control patients who do not receive cell delivery because hypoplastic left heart syndrome was not diagnosed before birth or cord blood was not collected.
-end-
Mayo Clinic and Dr. Nelson have a financial interest in the cord blood processing technology described in this press release.

About the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome

Founded in 2010, the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome is a collaborative network of specialists bonded by the vision of delaying or preventing heart failure for people affected by congenital heart defects, including hypoplastic left heart syndrome. The specialized team is addressing the various aspects of these defects by using research and clinical strategies ranging from basic science to diagnostic imaging to regenerative therapies.

About Mayo Clinic

Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, comprehensive care to everyone who needs healing. Learn more about Mayo Clinic. Visit the Mayo Clinic News Network.

Mayo Clinic

Related Stem Cells Articles:

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.
First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.
Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.
The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.
Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.
New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.
NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.
Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.
In mice, stem cells seem to work in fighting obesity! What about stem cells in humans?
This release aims to summarize the available literature in regard to the effect of Mesenchymal Stem Cells transplantation on obesity and related comorbidities from the animal model.
TSRI researchers identify gene responsible for mesenchymal stem cells' stem-ness'
Researchers at The Scripps Research Institute recently published a study in the journal Cell Death and Differentiation identifying factors crucial to mesenchymal stem cell differentiation, providing insight into how these cells should be studied for clinical purposes.
More Stem Cells News and Stem Cells Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.